FDA-cleared profile

Salix Coronary Plaque (V1.0.0)

Artrya Limited · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Salix Coronary Plaque (V1.0.0) is a web-based adjunctive tool for qualified cardiologists and radiologists to quantify and characterize coronary plaque and stenosis and perform calcium scoring from adult cardiac CT DICOM images.

Clinical role
Post-processing and quantitative coronary plaque, stenosis, and calcium assessment to support physician review of cardiac CT findings.
Images and patients
CT/CTA · Heart/Cardiovascular
Key limitation
Keep in mind: The software is adjunctive and interpolated views may appear normal for lesions at or below image resolution. Automated outputs and interpolated views require qualified clinical review; the FDA evidence is regulatory technical validation rather than independent clinical-outcome evidence.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Salix Coronary Plaque (V1.0.0) is a web-based adjunctive tool for qualified cardiologists and radiologists to quantify and characterize coronary plaque and stenosis and perform calcium scoring from adult cardiac CT DICOM images.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Cardiovascular Input: Adult CCTA or non-contrast calcium-scoring cardiac CT DICOM images acquired on a CT scanner.
  • Who uses it?Intended users: Qualified cardiologists and radiologists reviewing adult cardiac CT; the software is an adjunct and does not replace professional judgment.
  • What does the software produce?Output: Total, calcified, non-calcified, low-density non-calcified, and plaque-burden measurements; CAD-RADS stenosis grade; vessel and lumen profiles; calcium score; vessel centerlines, labels, and segmentations; and a coronary analysis report.
  • What is its most important limitation?Key limitation: The software is adjunctive and interpolated views may appear normal for lesions at or below image resolution. Automated outputs and interpolated views require qualified clinical review; the FDA evidence is regulatory technical validation rather than independent clinical-outcome evidence.

Clinical takeaway. Clinical role: Salix Coronary Plaque (V1.0.0) is a web-based adjunctive tool for qualified cardiologists and radiologists to quantify and characterize coronary plaque and stenosis and perform calcium scoring from adult cardiac CT DICOM images.

Evidence takeaway. Evidence from the reviewed source record: K251837 FDA evidence is a seven-center regulatory validation of Salix Coronary Plaque V1.0.0 outputs; no independent paper or trial was promoted in this timeboxed review.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Salix Coronary Plaque (V1.0.0) is a web-based adjunctive tool for qualified cardiologists and radiologists to quantify and characterize coronary plaque and stenosis and perform calcium scoring from adult cardiac CT DICOM images.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Post-processing and quantitative coronary plaque, stenosis, and calcium assessment to support physician review of cardiac CT findings.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
Adult CCTA or non-contrast calcium-scoring cardiac CT DICOM images acquired on a CT scanner.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
Total, calcified, non-calcified, low-density non-calcified, and plaque-burden measurements; CAD-RADS stenosis grade; vessel and lumen profiles; calcium score; vessel centerlines, labels, and segmentations; and a coronary analysis report.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Adult cardiac CT/CCTA interpretation in cardiology or radiology practice.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Qualified cardiologists and radiologists reviewing adult cardiac CT; the software is an adjunct and does not replace professional judgment.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
The software is adjunctive and interpolated views may appear normal for lesions at or below image resolution. Automated outputs and interpolated views require qualified clinical review; the FDA evidence is regulatory technical validation rather than independent clinical-outcome evidence.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
K251837 FDA evidence is a seven-center regulatory validation of Salix Coronary Plaque V1.0.0 outputs; no independent paper or trial was promoted in this timeboxed review.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K251837 FDA evidence is a seven-center regulatory validation of Salix Coronary Plaque V1.0.0 outputs; no independent paper or trial was promoted in this timeboxed review.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Vessel-level stenosis within one CAD-RADS category

95.8 percent

  • EndpointAgreement with reference stenosis category within one CAD-RADS category
  • Population103 adult patients from seven geographically diverse U.S. centers
  • Tested versionSalix Coronary Plaque Software Application V1.0.0

Total plaque volume ICC

0.96 ICC

  • EndpointAgreement of total plaque volume with reference
  • PopulationAdult cardiac CT validation cases
  • Tested versionSalix Coronary Plaque Software Application V1.0.0

Centerline overlap

0.8604 overlap coefficient

  • EndpointAgreement of extracted coronary centerline with reference
  • PopulationAdult cardiac CT validation cases
  • Tested versionSalix Coronary Plaque Software Application V1.0.0

K251837 Salix Coronary Plaque regulatory validation

  • DesignRetrospective multi-center regulatory validation of coronary plaque, stenosis, calcium, segmentation, and labeling outputs against reference annotations.
  • Population103 adult patients from seven geographically diverse U.S. centers; 302 non-contrast and 107 contrast series were reported across task-specific analyses.
  • Scopeexact submission
  • Tested versionSalix Coronary Plaque Software Application V1.0.0
  • Samplen=103
  • Sites7
  • IndependenceSponsor or vendor study

K251837

Manufacturer-submitted FDA evidence; it is not an independent clinical-outcome study.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The wave22 exact-submission recall query returned no native recall record for K251837. This does not establish absence of family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-07
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
CMS LCD L39913 v7 and Article A59813 v6 provide conditional service-level policy context for AI-QCT/AI-CPA after completed and interpreted CCTA in WPS Medicare J5/J8 for selected symptomatic chest-pain patients; exact product/version eligibility and individual claim eligibility are not established.
  • Product family
  • Checked 2026-09-07

Service-level policy context; exact product/version and individual claim eligibility are not established. This is not a product code assignment, universal Medicare coverage determination, fee, or price.

75577

Conditional service-level coverage; product eligibility unconfirmed

Medicare / WPS · United States - WPS J5/J8 jurisdictions · Effective 2026-01-01

CMS policy context applies to an eligible CCTA plaque-analysis service in a limited WPS policy scope; it does not assign coverage to K251837 or establish individual claim eligibility.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult CCTA or non-contrast calcium-scoring cardiac CT DICOM images acquired on a CT scanner.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K251837: Salix Coronary Plaque (V1.0.0)

  2. Routing

    Source context, not route validation: The exact submission accepts cardiac CT DICOM images and operates through a secured network server with image storage; site-specific PACS/RIS routing, identifiers, and report delivery require acceptance testing.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K251837: Salix Coronary Plaque (V1.0.0)

  3. AI processing

    Source context, not route validation: The FDA packet describes a web-based application with secured network-server integration and image storage; it does not establish the site hosting topology, retention, availability, or managed-service boundary for the exact release.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 · FDA 510(k) K251837: Salix Coronary Plaque (V1.0.0)

  4. Returned objects

    Source context, not route validation: Total, calcified, non-calcified, low-density non-calcified, and plaque-burden measurements; CAD-RADS stenosis grade; vessel and lumen profiles; calcium score; vessel centerlines, labels, and segmentations; and a coronary analysis report.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K251837: Salix Coronary Plaque (V1.0.0)

  5. Viewer/worklist/report

    Unresolved route: Total, calcified, non-calcified, low-density non-calcified, and plaque-burden measurements; CAD-RADS stenosis grade; vessel and lumen profiles; calcium score; vessel centerlines, labels, and segmentations; and a coronary analysis report.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K251837: Salix Coronary Plaque (V1.0.0)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA packet describes a web-based application with secured network-server integration and image storage; it does not establish the site hosting topology, retention, availability, or managed-service boundary for the exact release.
  • Exact FDA submission
  • Checked 2026-09-07
Integration
The exact submission accepts cardiac CT DICOM images and operates through a secured network server with image storage; site-specific PACS/RIS routing, identifiers, and report delivery require acceptance testing.
  • Exact FDA submission
  • Checked 2026-09-07
Training
Use requires qualified cardiologist or radiologist review of plaque, stenosis, calcium, and segmentation outputs; local onboarding should cover image eligibility, editing, interpolated-view limitations, reports, and escalation.
  • Exact FDA submission
  • Checked 2026-09-07
Monitoring
Monitor eligible CT series, segmentation and plaque edits, stenosis and calcium report completeness, failed or repeated analyses, PACS delivery, reader overrides, downtime, updates, complaints, and recalls by exact K251837 release.
  • Exact FDA submission
  • Checked 2026-09-07

Buyer acceptance guidance derived from the exact FDA workflow and validation scope; it is not a claimed vendor monitoring service.

Secured cardiac CT server workflow

The exact submission describes a web-based application accepting adult cardiac CT DICOM images through secured network-server integration with image storage; validate local PACS routing and identity mapping before use.

exact submission · checked 2026-09-07

Artrya Salix family workflow

Artrya's current Salix indication describes a web-based tool for trained professionals that supports cardiac CT plaque, stenosis, and calcium scoring on CT data from any CT scanner as an adjunct to clinical judgment.

product family · checked 2026-09-07

Current family indication; confirm exact K251837 version, scanner compatibility, hosting, licensing, and local interfaces.

Report and segmentation acceptance

Buyer acceptance should test vessel labeling, centerline and wall segmentation edits, plaque composition outputs, CAD-RADS reporting, non-contrast calcium workflow, and behavior near image-resolution limits.

exact submission · checked 2026-09-07
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K251837
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Heart/Cardiovascular
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-08-20
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The stored PubMed and ClinicalTrials.gov candidate arrays were screened and were empty. No paper or trial was promoted; empty stored arrays do not establish that no external literature or trials exist. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, payer policy, fda device recall, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-07 - Exact FDA submission

    No public list price or contract unit for the exact K251837 configuration was established in the reviewed official sources.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-07 - Exact FDA submission

    The reviewed exact packet and Artrya family indication page do not establish current scoped security controls, certification scope, PHI flow, retention, access control, audit, or incident response for K251837.

  • Installation timeline: Not yet reviewed

10 sources - 3 history items

Source ledger

  1. FDA 510(k) K251837: Salix Coronary Plaque (V1.0.0)

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: identity, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, integration, deployment, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Salix Coronary Plaque (V1.0.0) model card (K251837)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Artrya Salix indications for use and user guide entry

    Artrya Limited - Accessed 2026-09-07

    Scope: productFamily, clinicalUse, intendedUsers, limitations, implementationCapabilities

  8. openFDA exact recall query for K251837

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: postmarketSafety

  9. CMS LCD L39913 version 7

    Centers for Medicare & Medicaid Services - Accessed 2026-09-07

    Scope: reimbursementPolicy

  10. CMS Article A59813 version 6

    Centers for Medicare & Medicaid Services - Accessed 2026-09-07

    Scope: reimbursementPolicy

Research history

  1. K251837 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252217

CT VScore+

Canon Medical Informatics, Inc.

Authorized purpose: CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and highlighted calcium segmentation for qualified clinical review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-11-28
FDA-cleared K251027

cvi42 Coronary Plaque Software Application

Circle Cardiovascular Imaging, Inc.

Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-10-27
FDA-cleared K251656

Careverse CoronaryDoc (Careverse CoronaryDoc)

Careverse Technology Pte. Ltd.

Authorized purpose: Careverse CoronaryDoc is a web-based tool for trained medical professionals to view and analyze CCTA CT data for coronary plaques and stenosis, with coronary measurements, visualization, automated plaque and stenosis outputs, and structured reporting for physician review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-09-04

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history